The mission of Pharmacoanalytical Laboratory (PAL) is to provide intellectual and analytical support to basic, translational and clinical scientists. For basic science investigators, the PAL assists in the development of discoveries from the """"""""test tube"""""""" to potential clinical modalities. Potential anticancer or diagnostic agents derived from laboratory concepts are further developed using in vitro and in vivo models developed with intellectual support from the PAL. For clinicians, the PAL provides analytical and pharmacokinetic/pharmacodynamics support to further understand the underlying mechanisms that may influence clinical outcome. In an effort to meet these needs, the PAL has acquired the capacity to develop specific analytical and biologically-based techniques to support basic, translational and clinically-based efforts. This includes the development of highly sensitive quantification methods by using ELISA- and liquid chromatography tandem mass spectrometry (LC-MS/MS)-based technology. LC-MS/MS-based technology can minimize the amount of sample volume required, thus allowing serial drug analysis in pediatric populations and even in small animals. In addition, the PAL has developed methods using LC-MS/MS to determine intracellular concentration nucleosides and their anabolites that include the activated component, the triphosphate nucleotides. These techniques can also be used to analyze intracellular nucleotide pools to study cellular mechanisms that lead to nucleoside resistance. In addition, the PAL collaborates in the design of clinical protocols having a pharmacokinetic component and evaluates the results of human pharmacokinetic studies. Despite these developments, the PAL has maintained and enhanced its core analytical capacity using HPLC-based assays utilizing UV and fluorescence detection. These assays are reliable analytical capabilities that can support clinical protocols that mandate drug level determinations. The PAL fosters an environment to enhance collaboration between basic, translational and clinical scientists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-35
Application #
8056489
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
35
Fiscal Year
2010
Total Cost
$147,914
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880
Ryser, Marc D; Min, Byung-Hoon; Siegmund, Kimberly D et al. (2018) Spatial mutation patterns as markers of early colorectal tumor cell mobility. Proc Natl Acad Sci U S A 115:5774-5779
Rhie, Suhn Kyong; Schreiner, Shannon; Farnham, Peggy J (2018) Defining Regulatory Elements in the Human Genome Using Nucleosome Occupancy and Methylome Sequencing (NOMe-Seq). Methods Mol Biol 1766:209-229
Zhou, Beiyun; Flodby, Per; Luo, Jiao et al. (2018) Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis. J Clin Invest 128:970-984
Nguyen, Lisa; Wang, Zheng; Chowdhury, Adnan Y et al. (2018) Functional compensation between hematopoietic stem cell clones in vivo. EMBO Rep 19:
Jadvar, Hossein; Chen, Xiaoyuan; Cai, Weibo et al. (2018) Radiotheranostics in Cancer Diagnosis and Management. Radiology 286:388-400
Tokunaga, Ryuma; Zhang, Wu; Naseem, Madiha et al. (2018) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev 63:40-47
Khanova, Elena; Wu, Raymond; Wang, Wen et al. (2018) Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology 67:1737-1753
McSkane, Michelle; Stintzing, Sebastian; Heinemann, Volker et al. (2018) Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. Clin Colorectal Cancer 17:215-222.e3

Showing the most recent 10 out of 842 publications